公开(公告)号：US20050234538A1

公开(公告)日：2005-10-20

申请号：US11096774

申请日：2005-03-31

申请人： Frank Litvack ,  Jonh Shanley ,  Theodore Parker ,  Stephen Diaz

发明人： Frank Litvack ,  Jonh Shanley ,  Theodore Parker ,  Stephen Diaz

IPC分类号： A61F2/00 ,  A61F2/02 ,  A61F2/06 ,  A61F2/84 ,  A61L31/16 ,  A61M25/10

CPC分类号： A61F2/958 ,  A61F2210/0004 ,  A61F2250/0068

摘要： A method and system for delivering a bioresorbable intravascular stent includes a delivery system or catheter having an expandable balloon. A guidewire lumen having a distal guidewire port and a proximal guidewire port spaced a relatively short distance from the distal end allows rapid exchange of the stent delivery system over a guidewire.

摘要翻译： 用于递送生物可再吸收的血管内支架的方法和系统包括具有可膨胀气囊的输送系统或导管。 具有远端导丝端口和与远端间隔相对较短距离的近端导丝端口的导丝管腔允许通过导丝线快速更换支架输送系统。

公开(公告)号：US20060178734A1

公开(公告)日：2006-08-10

申请号：US11325223

申请日：2006-01-04

申请人： Theodore Parker ,  John Shanley ,  Brett Trauthen ,  Frank Litvack ,  Stephen Diaz

发明人： Theodore Parker ,  John Shanley ,  Brett Trauthen ,  Frank Litvack ,  Stephen Diaz

IPC分类号： A61F2/06

CPC分类号： A61L31/16 ,  A61F2/91 ,  A61F2210/0004 ,  A61F2230/0054 ,  A61F2250/0068 ,  A61L2300/416 ,  A61L2300/602

摘要： A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled, extended, and substantially linear drug release profile. The method of substantially linear extended release increases the therapeutic effectiveness of administration of a given dosage. In one example, a method of reducing restenosis includes delivering paclitaxel from a stent to an artery at a minimum release rate of 1 percent of the total dosage of paclitaxel on the stent per day throughout an entire administration period from the time of implantation of the stent until the time that substantially all the paclitaxel is released from the stent.

摘要翻译： 用于降低支架置入医疗干预后再狭窄水平的方法包括将需要治疗的受支配物，延长和基本上的支架的支架到血管组织的持续施用一定剂量的抗再狭窄剂如紫杉醇 线性药物释放曲线。 基本线性延长释放的方法增加给药剂量的给药的治疗有效性。 在一个实例中，减少再狭窄的方法包括将紫杉醇从支架输送到动脉，在从支架植入开始的整个施用期间，每天在支架上以最大释放速率将紫杉醇的总剂量的1％ 直到基本上所有的紫杉醇从支架释放出来。

公开(公告)号：US20070269486A1

公开(公告)日：2007-11-22

申请号：US11696360

申请日：2007-04-04

申请人： Theodore Parker ,  Thai Nguyen ,  John Shanley ,  Frank Litvack

发明人： Theodore Parker ,  Thai Nguyen ,  John Shanley ,  Frank Litvack

IPC分类号： A61F2/06 ,  A61K31/337 ,  A61K31/4353 ,  A61K38/28 ,  A61P9/00

CPC分类号： A61K31/337 ,  A61F2/91 ,  A61F2250/003 ,  A61F2250/0068 ,  A61K38/28 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/45

摘要： Methods and devices are provided for the delivery of therapeutic agents which reduce myocardial tissue damage due to ischemia and anti-restenotic agents which inhibit restenosis following a cardiac procedure such as stent implantation. The anti-ischemia agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction in ischemic or reperfusion injury of the myocardial tissue. The anti-restenotic agents are delivered over an administration period sufficient to reduce the re-narrowing of a blood vessel following a cardiac procedure such as implantation of a device. Preferred anti-restenotic drugs are those that do not reduce the beneficial effects provided by the anti-ischemic drug, such as drugs that do not act on the mammalian target of rapamycin (mTOR).

摘要翻译： 提供了用于递送治疗剂的方法和装置，其减少由于局部缺血引起的心肌组织损伤和在心脏手术如支架植入之后抑制再狭窄的抗再狭窄剂。 在足以实现心肌组织的缺血或再灌注损伤减少的给药期间将抗缺血剂递送至心肌组织。 抗再狭窄剂在足以减少心脏手术如植入装置后的血管再狭窄的给药期内递送。 优选的抗再狭窄药物是不减少由抗缺血药物提供的有益效果的那些，例如不作用于雷帕霉素哺乳动物靶标（mTOR）的药物。

公开(公告)号：US20060122697A1

公开(公告)日：2006-06-08

申请号：US11079967

申请日：2005-03-14

申请人： John Shanley ,  Frank Litvack ,  Theodore Parker ,  Thai Nguyen

发明人： John Shanley ,  Frank Litvack ,  Theodore Parker ,  Thai Nguyen

IPC分类号： A61F2/06

CPC分类号： A61F2/856 ,  A61F2/91 ,  A61F2/915 ,  A61F2002/91508 ,  A61F2002/91516 ,  A61F2002/91525 ,  A61F2002/91541 ,  A61F2002/91558 ,  A61F2250/0035 ,  A61F2250/0068 ,  A61L31/10 ,  A61L31/146 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/45 ,  A61L2300/602

摘要： An expandable medical device includes a plurality of elongated struts, forming a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter. A plurality of different beneficial agents can be loaded into different openings within the struts for delivery to the tissue. For treatment of conditions such as restenosis, different beneficial agents are loaded into different openings in the device to address different biological processes involved in restenosis and are delivered at different release kinetics matched to the biological process treated. The different beneficial agents may also be used to address different diseases, such as restenosis and acute myocardial infarction from the same drug delivery device.

摘要翻译： 可扩张医疗装置包括多个细长的支柱，形成基本上圆柱形的装置，其可从具有第一直径的圆柱体扩展到具有第二直径的圆柱体。 多个不同的有益剂可以被装载到支柱内的不同的开口中以便递送到组织。 为了治疗诸如再狭窄的病症，将不同的有益药物装入装置的不同开口中以解决与再狭窄有关的不同生物过程，并且以与所治疗的生物过程相匹配的不同释放动力学递送。 不同的有益药物也可用于解决来自同一药物递送装置的不同疾病，例如再狭窄和急性心肌梗塞。

公开(公告)号：US20070112414A1

公开(公告)日：2007-05-17

申请号：US11516054

申请日：2006-09-05

申请人： Theodore Parker ,  Frank Litvack ,  Micheline Lisa Markey

发明人： Theodore Parker ,  Frank Litvack ,  Micheline Lisa Markey

IPC分类号： A61F2/06

CPC分类号： A61L31/16 ,  A61L31/146 ,  A61L2300/21 ,  A61L2300/402 ,  A61L2300/416 ,  A61L2300/42

摘要： Dipyridamole is an antithrombotic agent which also promotes the growth of endothelial cells. An endothelial cell lining within a stent is necessary for complete healing on the interior of the stent. A dual drug dipyridamole stent includes a first drug formulation of dipyridamole and polymer arranged in a first set of holes in the stent for primarily luminal delivery and a second drug formulation of an antirestenotic agent and polymer arranged in a second set of holes in the stent for primarily mural delivery. The delivery of dipyridamole luminally into the blood stream can involve a two phase release with the first phase being a burst to prevent initial clotting or thrombus formation followed by a second phase with a much slower and more sustained release to reduce thrombogenicity and promote the growth of the endothelial cell lining.

摘要翻译： 双嘧达莫是一种还促进内皮细胞生长的抗血栓形成剂。 支架内部的内皮细胞衬里对于在支架内部完全愈合是必需的。 双药双嘧达莫支架包括双嘧达莫的第一药物制剂和布置在支架中的第一组孔中的聚合物，用于主要的腔内递送，以及布置在支架中的第二组孔中的抗再狭窄剂和聚合物的第二药物制剂， 主要是壁画交付。 将双嘧达莫光发射到血液中可涉及两相释放，第一阶段是爆发，以防止初始凝血或血栓形成，随后是具有更慢和更持续释放的第二相以降低血栓形成并促进生长 内皮细胞内衬。

公开(公告)号：US20060002975A1

公开(公告)日：2006-01-05

申请号：US11213570

申请日：2005-08-26

申请人： Frank Litvack ,  Theodore Parker ,  John Shanley

发明人： Frank Litvack ,  Theodore Parker ,  John Shanley

IPC分类号： A61M31/00 ,  A61F2/00

CPC分类号： A61L31/14 ,  A61F2/91 ,  A61F2/915 ,  A61F2/958 ,  A61F2002/91541 ,  A61F2250/0068 ,  A61K38/28 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/43

摘要： A method and apparatus for the local delivery of therapeutic agents reduces myocardial tissue damage due to ischemia. A local delivery device is used for delivery of the therapeutic agents into a coronary artery which feeds the ischemic myocardial tissue. According to one example, an implantable medical device for delivering insulin locally to myocardial tissue includes a therapeutic dosage of insulin in a biocompatible polymer affixed to a stent. The therapeutic dosage of insulin is released from the stent at a therapeutic dosage and over an administration period effective to reduce ischemic injury of the myocardial tissue.

摘要翻译： 用于局部递送治疗剂的方法和装置减少由缺血引起的心肌组织损伤。 局部递送装置用于将治疗剂递送到进行缺血性心肌组织的冠状动脉中。 根据一个示例，用于将胰岛素局部递送至心肌组织的可植入医疗装置包括固定在支架上的生物相容性聚合物中的治疗剂量的胰岛素。 胰岛素的治疗剂量以治疗剂量和超过有效减少心肌组织缺血性损伤的给药期从支架释放。

公开(公告)号：US20060079956A1

公开(公告)日：2006-04-13

申请号：US11200765

申请日：2005-08-10

申请人： Neal Eigler ,  Frank Litvack ,  John Shanley ,  Stephen Diaz

发明人： Neal Eigler ,  Frank Litvack ,  John Shanley ,  Stephen Diaz

IPC分类号： A61F2/06

CPC分类号： A61F2/856 ,  A61F2/852 ,  A61F2/91 ,  A61F2/915 ,  A61F2/954 ,  A61F2/958 ,  A61F2002/91541 ,  A61F2002/91558 ,  A61F2250/0018 ,  A61F2250/0039 ,  A61F2250/0068

摘要： A bifurcation stent includes a first end which is deformable or crushable at a lower force than a second end. The crushable first end and more rigid second end of the bifurcation stent allow one end of the stent to remain expanded in tissue supporting configuration in a side branch of a vessel bifurcation while the other end is easily crushed against the side wall of the main vessel into which it extends. A method of supporting a bifurcated body lumen with the bifurcation stent involves delivering the bifurcation stent in an unexpanded configuration to a bifurcation in a body lumen, positioning the bifurcation stent with the distal portion substantially within a side branch vessel of the bifurcation and the proximal crushable portion substantially within the main vessel, expanding the bifurcation stent, and expanding a main vessel stent along side the bifurcation stent and thereby crushing at least a portion of the crushable proximal portion of the bifurcation stent against the main vessel wall.

摘要翻译： 分叉支架包括可在比第二端更低的力下变形或可压碎的第一端。 分叉支架的可破碎的第一端和更刚性的第二端允许支架的一端在血管分叉的侧支中的组织支撑构型中保持膨胀，而另一端容易被压在主血管的侧壁上 它扩展了。 使用分叉支架支撑分叉体腔的方法包括将未扩张构型中的分叉支架递送到体腔中的分叉，将分叉支架与远端部分基本上位于分叉的侧分支血管中并将近端可压溃 部分基本上在主容器内部，扩张分叉支架，并且使主血管支架沿着分叉支架一侧扩张，从而将分叉支架的可压溃近端部分的至少一部分压碎在主血管壁上。

公开(公告)号：US20060204546A1

公开(公告)日：2006-09-14

申请号：US11375454

申请日：2006-03-14

申请人： Thai Nguyen ,  John Shanley ,  Frank Litvack ,  Theodore Parker

发明人： Thai Nguyen ,  John Shanley ,  Frank Litvack ,  Theodore Parker

IPC分类号： A61F2/06

CPC分类号： A61F2/915 ,  A61F2/91 ,  A61F2002/91541 ,  A61F2250/0068 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416

摘要： A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an immunosuppressant or anti-inflammatory agent from reservoirs in a stent to vascular tissue in need of treatment in a controlled, two phase drug release profile. It is envisioned that the vascular tissue in need of treatment is arterial tissue, specifically coronary arterial tissue. The agent or drug can be the calcineurin inhibitor Pimecrolimus. The drug can be held within reservoirs in the stent in a drug delivery matrix comprised of the drug and a bioresorbable polymeric material and optionally additives to regulate the drug release.

摘要翻译： 用于降低支架置入医疗干预后再狭窄水平的方法包括将需要在受控的两相药物释放曲线中进行治疗的支架中的血管中的一个剂量的免疫抑制剂或抗炎药剂的剂量连续施用于血管组织 。 可以想象，需要治疗的血管组织是动脉组织，特别是冠状动脉组织。 该药物或药物可以是钙调神经磷酸酶抑制剂Pimecrolimus。 该药物可以在由药物和生物可再吸收的聚合物材料和任选的调节药物释放的添加剂的药物递送基质中的支架内的储存器中保持。

公开(公告)号：US20070191935A1

公开(公告)日：2007-08-16

申请号：US11671642

申请日：2007-02-06

申请人： Theodore Parker ,  John Shanley ,  Frank Litvack

发明人： Theodore Parker ,  John Shanley ,  Frank Litvack

IPC分类号： A61F2/06

CPC分类号： A61L31/16 ,  A61F2/91 ,  A61F2250/0068 ,  A61L2300/416 ,  A61L2300/602

摘要： A method for reducing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled and extended drug release profile for a period of at least 60 days in vivo. The in vivo release profile is determined by in vivo animal experiments involving implanting a series of stents in animals, explanting the stents from the animals at selected time points, and extracting remaining drug from the explanted stents.

摘要翻译： 用于降低支架置入医疗干预后再狭窄水平的方法包括从支架到需要在受控和延长的药物释放曲线中治疗的血管组织连续施用一定剂量的抗再狭窄剂（例如紫杉醇） 在体内至少60天的时间。 通过体内动物实验确定体内释放曲线，包括在动物中植入一系列支架，在选定的时间点从动物外植体支架，以及从移植的支架中提取剩余的药物。

公开(公告)号：US20060204547A1

公开(公告)日：2006-09-14

申请号：US11375595

申请日：2006-03-14

申请人： Thai Nguyen ,  John Shanley ,  Frank Litvack ,  Theodore Parker

发明人： Thai Nguyen ,  John Shanley ,  Frank Litvack ,  Theodore Parker

IPC分类号： A61K31/4745 ,  A61F2/06

CPC分类号： A61F2/915 ,  A61F2/91 ,  A61F2002/91541 ,  A61F2250/0068 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416

摘要： A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as Pimecrolimus, from the stent to vascular tissue in need of treatment in a controlled and extended drug release profile for a period of at least 45 days in vivo. The in vivo release profile is determined by in vivo animal experiments involving implanting a series of stents in animals, explanting the stents from the animals at selected time points, and extracting remaining drug from the explanted stents.

摘要翻译： 用于降低支架放置医疗干预后再狭窄水平的方法包括将需要在受控和延长的药物释放曲线中进行治疗的支架到维管组织连续施用一定剂量的抗再狭窄剂如吡美莫司，从支架到血管组织 在体内至少45天的时间。 通过体内动物实验确定体内释放曲线，包括在动物中植入一系列支架，在选定的时间点从动物外植体支架，以及从移植的支架中提取剩余的药物。